CFR shareholders OK new $1.2B Adcock bid; Aurobindo said to be eyeing Actavis API units; Isentress formula wins FDA nod for infants;

@FiercePharma: AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story from FierceVaccines | Follow @FiercePharma

@TracyStaton: And still FiercePharma's best-read special report: Top 10 Drug Patent Losses of 2014. Report | Follow @TracyStaton

@EricPFierce: There are 3,000 compounding pharmacies making sterile drugs. Just 11 have volunteered for FDA oversight. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Adcock Ingram forges ahead with its African expansion while CFR deal stalls. Friday's story | Follow @CarlyHFierce

> Shareholders of Chile-based drugmaker CFR Pharmaceuticals approved a higher bid for South Africa's Adcock Ingram, where recalcitrant shareholders are holding up a deal. Report

> India's Aurobindo Pharma is reportedly in talks to buy active pharmaceutical ingredient operations from U.S.-based Actavis ($ACT). Report

> A liquid formulation of Merck's ($MRK) HIV-fighting drug Isentress won FDA approval for infants infected with the virus. Report

> India's Cadila Pharmaceuticals linked up with Sweden's NovaSAID to develop treatments for inflammatory conditions such as rheumatoid arthritis, with Cadila paying development costs and retaining rights to sales in India, West Asia and Africa. Report

> China-based drugmaker Jiangsu Aosaikang delayed its share sale just days after the country reopened its IPO market. Report

Medical Device News

@FierceMedDev: Appeals court reaffirms injunction on Boston Scientific's Guidezilla catheter. More | Follow @FierceMedDev

@MarkHFierce: Detailed medical imaging of the skin is drawing investor interest in the U.K. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: O.C. medical device firm sees great potential in Indian market, expands sales. More | Follow @EmilyWFierce

> St. Jude points to solid Q4 growth in an early earnings release. Story

> Ivantis' $46.5M Series B will propel multiple trials for a tiny eye stent. Article

> Cancer Dx startup Microlin Bio envisions $25M IPO. Item

Biotech News

@FierceBiotech: Merck's fast and furious MK-3475 #immunotherapy team guns for a quick approval. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Sanofi and Roche going deeper into RNAi as Merck bails out, takes a big writeoff for Sirna. Makes sense, though. In or out. | Follow @JohnCFierce

@DamianFierce: With $125M Alexion deal, Moderna has pulled in more than $500M over the past year and change. More | Follow @DamianFierce

@EmilyMFierce: European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Article | Follow @EmilyMFierce

> GSK dumps a failed muscular dystrophy drug back in Prosensa's lap. Story

> Cell Therapeutics buoyed as Novartis deals are terminated. More

> Sanofi grabs a $700M stake in Alnylam as it ups the ante on RNAi. News

CRO News

> Quintiles partners up to boost its commercialization business. More

> Theorem aligns with BioTelemetry to dial up its cardiac market share. Report

> CROS NT buys into biometrics with its latest acquisition. News

> Pfizer taps risk-sharing researcher Avillion for cancer PhIII. Story

> JSS eyes Canadian dominance with buyout of rival CRO. Article

> GoBalto goes global with expansion into U.K. and Singapore. Item

Biotech IT News

> New York Genome Center taps U. of Buffalo for computing horsepower. Report

> Pfizer trialing video game designed to diagnose Alzheimer's. Item

> Merge wipes $15M from backlog after discovering ex-employee faked contracts. News

> Merck invests in an FDA-cleared mobile diabetes management business. Article

> Analyst: CROs like Covance and Icon will take the lead on IT and genomics. Story

> Early Google investor picks Maverix from the genome data analysis crowd. More

And Finally ... Is Google's ($GOOG) X research group working with the FDA on a new medical device? Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.